Speculative buy now: price is sitting just above a key pivot/support zone (~31.47) after a sharp -7.05% regular-session drop, creating a favorable near-term bounce setup for an impatient buyer.
Trend structure is still bullish on moving averages (SMA_5 > SMA_20 > SMA_200), suggesting the pullback is more likely a reset than a full trend break.
Options positioning is mildly bullish (puts not dominating), and Evercore’s $65 target implies substantial upside if 2026 catalysts land.
This is a development-stage biotech with high volatility; the “buy” call is based on technical positioning + sentiment, not on current fundamentals.
Technical Analysis
Price/levels: Post-market ~31.93, hovering just above Pivot 31.467 (near-term decision level). Upside resistances: R1 34.89, then R2 37.005. Downside supports: S1 28.045, then S2 25.93.
Flow: Volume is extremely light (only 3 contracts total; calls=2, puts=1), so today’s options read is low-confidence.
Volatility: 30D IV ~138.91 vs HV ~129.61 (still very high absolute vol), but IV percentile ~25.5 / IV rank ~7.79 indicates IV is relatively low versus its own recent history—often supportive for long exposure into catalyst windows.
Technical Summary
Sell
5
Buy
8
Positive Catalysts
while the longer trend (moving averages) remains bullish.
Neutral/Negative Catalysts
Short-term momentum is deteriorating (MACD histogram negative and expanding), raising risk of follow-through weakness before any rebound.
No news in the past week: lack of near-term catalysts can leave the stock trading purely on technicals/flows.
Trading trends: Hedge funds and insiders are reported neutral (no supportive accumulation signal).
Extremely high volatility profile (both historical and implied) can lead to abrupt swings around support/resistance.
Financial Performance
Latest quarter provided: 2025/Q3.
Revenue: 0 (no operating revenue; typical for development-stage biotech).
Net income: -17.682M, improved YoY (loss narrowed vs prior year per +110.70% figure), but still deeply negative.
Takeaway: fundamentals are still R&D/cash-burn driven; price action is likely to be catalyst/expectations-led rather than earnings-led.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
2025-11-25: Evercore ISI initiated coverage at Outperform with a $65 price target.
Rationale highlights: re-rating trend in proof-of-concept-focused microcaps; FBRX viewed as fitting that bucket; setup described as “super attractive into a catalyst-rich 2026.”
Wall Street-style pros: strong upside framing into 2026 catalysts; belief the stock had lagged peers until recently.
Wall Street-style cons: coverage appears limited (single initiation shown); thesis is catalyst-dependent rather than supported by current revenue/earnings.
Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65 USD with a low forecast of 65 USD and a high forecast of 65 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is 65 USD with a low forecast of 65 USD and a high forecast of 65 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 28.810
Low
65
Averages
65
High
65
Current: 28.810
Low
65
Averages
65
High
65
Evercore ISI
Outperform
initiated
$65
AI Analysis
2025-11-25
Reason
Evercore ISI
Price Target
$65
AI Analysis
2025-11-25
initiated
Outperform
Reason
Evercore ISI initiated coverage of Forte Biosciences with an Outperform rating and $65 price target. There has been a notable re-rating in development-stage microcap companies, especially those with important proof of concept data in 2025 and 2026, notes the analyst. While arguing that Forte "falls squarely in this bucket," the firm notes shares have been slow to get the same bid until the last two weeks, adding that it thinks the setup is "super attractive into a catalyst-rich 2026."
Guggenheim
NULL -> Buy
initiated
$75
2025-08-18
Reason
Guggenheim
Price Target
$75
2025-08-18
initiated
NULL -> Buy
Reason
Guggenheim initiated coverage of Forte Biosciences with a Buy rating and $75 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for FBRX
